Copyright © 2009 Saoirse E. O'Sullivan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. J. Janke, M. Schupp, S. Engeli, et al., “Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-$\gamma$ activation,” Journal of Hypertension, vol. 24, no. 9, pp. 1809–1816, 2006. View at Publisher · View at Google Scholar · View at PubMed
2. M. Jasińska, J. Owczarek, and D. Orszulak-Michalak, “Statins: a new insight into their mechanisms of action and consequent pleiotropic effects,” Pharmacological Reports, vol. 59, no. 5, pp. 483–499, 2007.
3. M. Schupp, J. C. Curtin, R. J. Kim, A. N. Billin, and M. A. Lazar, “A widely used retinoic acid receptor antagonist induces peroxisome proliferator-activated receptor-$\gamma$ activity,” Molecular Pharmacology, vol. 71, no. 5, pp. 1251–1257, 2007. View at Publisher · View at Google Scholar · View at PubMed
4. N. K. Salam, T. H.-W. Huang, B. P. Kota, M. S. Kim, Y. Li, and D. E. Hibbs, “Novel PPAR-gamma agonists identified from a natural product library: a virtual screening, induced-fit docking and biological assay study,” Chemical Biology & Drug Design, vol. 71, no. 1, pp. 57–70, 2008.
5. K. Kuroyanagi, M.-S. Kang, T. Goto, et al., “Citrus auraptene acts as an agonist for PPARs and enhances adiponectin production and MCP-1 reduction in 3T3-L1 adipocytes,” Biochemical and Biophysical Research Communications, vol. 366, no. 1, pp. 219–225, 2008. View at Publisher · View at Google Scholar · View at PubMed
6. S. E. O'Sullivan, “Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors,” British Journal of Pharmacology, vol. 152, no. 5, pp. 576–582, 2007. View at Publisher · View at Google Scholar · View at PubMed
7. K. R. Kozak, R. A. Gupta, J. S. Moody, et al., “15-lipoxygenase metabolism of 2-arachidonylglycerol: generation of a peroxisome proliferator-activated receptor $\alpha$ agonist,” The Journal of Biological Chemistry, vol. 277, no. 26, pp. 23278–23286, 2002. View at Publisher · View at Google Scholar · View at PubMed
8. J. Fu, S. Gaetani, F. Oveisi, et al., “Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-$\alpha$,” Nature, vol. 425, no. 6953, pp. 90–93, 2003. View at Publisher · View at Google Scholar · View at PubMed
9. M. Guzmán, J. Lo Verme, J. Fu, F. Oveisi, C. Blázquez, and D. Piomelli, “Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor $\alpha$ (PPAR-$\alpha$),” The Journal of Biological Chemistry, vol. 279, no. 27, pp. 27849–27854, 2004. View at Publisher · View at Google Scholar · View at PubMed
10. J. Lo Verme, J. Fu, G. Astarita, et al., “The nuclear receptor peroxisome proliferator-activated receptor-$\alpha$ mediates the anti-inflammatory actions of palmitoylethanolamide,” Molecular Pharmacology, vol. 67, no. 1, pp. 15–19, 2005. View at Publisher · View at Google Scholar · View at PubMed
11. Y. Sun, S. P. H. Alexander, D. A. Kendall, and A. J. Bennett, “Cannabinoids and PPAR$\alpha$ signalling,” Biochemical Society Transactions, vol. 34, no. 6, pp. 1095–1097, 2006. View at Publisher · View at Google Scholar · View at PubMed
12. J. Liu, H. Li, S. H. Burstein, R. B. Zurier, and J. D. Chen, “Activation and binding of peroxisome proliferator-activated receptor $\gamma$ by synthetic cannabinoid ajulemic acid,” Molecular Pharmacology, vol. 63, no. 5, pp. 983–992, 2003. View at Publisher · View at Google Scholar
13. S. E. O'Sullivan, E. J. Tarling, A. J. Bennett, D. A. Kendall, and M. D. Randall, “Novel time-dependent vascular actions of ${\mathrm{\Delta }}^9$- tetrahydrocannabinol mediated by peroxisome proliferator-activated receptor gamma,” Biochemical and Biophysical Research Communications, vol. 337, no. 3, pp. 824–831, 2005. View at Publisher · View at Google Scholar · View at PubMed
14. C. E. Rockwell and N. E. Kaminski, “A cyclooxygenase metabolite of anandamide causes inhibition of interleukin-2 secretion in murine splenocytes,” Journal of Pharmacology and Experimental Therapeutics, vol. 311, no. 2, pp. 683–690, 2004. View at Publisher · View at Google Scholar · View at PubMed
15. C. E. Rockwell, N. T. Snider, J. T. Thompson, J. P. Vanden Heuvel, and N. E. Kaminski, “Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor $\gamma$ independently of cannabinoid receptors 1 and 2,” Molecular Pharmacology, vol. 70, no. 1, pp. 101–111, 2006. View at Publisher · View at Google Scholar · View at PubMed
16. M. Bouaboula, S. Hilairet, J. Marchand, L. Fajas, G. Le Fur, and P. Casellas, “Anandamide induced PPAR$\gamma$ transcriptional activation and 3T3-L1 preadipocyte differentiation,” European Journal of Pharmacology, vol. 517, no. 3, pp. 174–181, 2005. View at Publisher · View at Google Scholar · View at PubMed
17. V. Gasperi, F. Fezza, N. Pasquariello, et al., “Endocannabinoids in adipocytes during differentiation and their role in glucose uptake,” Cellular and Molecular Life Sciences, vol. 64, no. 2, pp. 219–229, 2007. View at Publisher · View at Google Scholar · View at PubMed
18. S. E. O'Sullivan, A. J. Bennett, D. A. Kendall, and M. D. Randall, “Cannabinoids and peroxisome proliferator-activated receptor gamma (PPAR$\gamma$),” in Proceedings of the International Cannabinoid Research Society (ICRS '06), p. 59, Tihany, Hungary, June 2006.
19. S. E. O'Sullivan, D. A. Kendall, and M. D. Randall, “Further characterization of the time-dependent vascular effects of ${\mathrm{\Delta }}^9$-tetrahydrocannabinol,” Journal of Pharmacology and Experimental Therapeutics, vol. 317, no. 1, pp. 428–438, 2006. View at Publisher · View at Google Scholar · View at PubMed
20. J. Hwang, D. J. Kleinhenz, B. Lassègue, K. K. Griendling, S. Dikalov, and C. M. Hart, “Peroxisome proliferator-activated receptor-$\gamma$ ligands regulate endothelial membrane superoxide production,” American Journal of Physiology, vol. 288, no. 4, pp. C899–C905, 2005. View at Publisher · View at Google Scholar · View at PubMed
21. P. M. Zygmunt, J. Petersson, D. A. Andersson, et al., “Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide,” Nature, vol. 400, no. 6743, pp. 452–457, 1999. View at Publisher · View at Google Scholar · View at PubMed
22. D. Harris, A. I. McCulloch, D. A. Kendall, and M. D. Randall, “Characterization of vasorelaxant responses to anandamide in the rat mesenteric arterial bed,” Journal of Physiology, vol. 539, no. 3, pp. 893–902, 2002. View at Publisher · View at Google Scholar
23. S. E. O'Sullivan, D. A. Kendall, and M. D. Randall, “Vascular effects of ${\mathrm{\Delta }}^9$-tetrahydrocannabinol (THC), anandamide and N-arachidonoyldopamine (NADA) in the rat isolated aorta,” European Journal of Pharmacology, vol. 507, no. 1–3, pp. 211–221, 2005. View at Publisher · View at Google Scholar · View at PubMed
24. L. Offertáler, F.-M. Mo, S. Bátkai, et al., “Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor,” Molecular Pharmacology, vol. 63, no. 3, pp. 699–705, 2003. View at Publisher · View at Google Scholar
25. P. M. Hoi and C. R. Hiley, “Vasorelaxant effects of oleamide in rat small mesenteric artery indicate action at a novel cannabinoid receptor,” British Journal of Pharmacology, vol. 147, no. 5, pp. 560–568, 2006. View at Publisher · View at Google Scholar · View at PubMed
26. S. E. Cunnane, Y. Y. Chan, and M. D. Randall, “Rosiglitazone-induced vasorelaxation in the rat aorta,” Proceedings of the British Pharmacological Society, vol. 2, no. 2, abstract 096P, 2004.
27. M. D. Randall, D. A. Kendall, and S. E. O'Sullivan, “The complexities of the cardiovascular actions of cannabinoids,” British Journal of Pharmacology, vol. 142, no. 1, pp. 20–26, 2004. View at Publisher · View at Google Scholar · View at PubMed
28. M. Yano, T. Matsumura, T. Senokuchi, et al., “Statins activate peroxisome proliferator-activated receptor $\gamma$ through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages,” Circulation Research, vol. 100, no. 10, pp. 1442–1451, 2007. View at Publisher · View at Google Scholar · View at PubMed
29. B. L. Upham, A. M. Rummel, J. M. Carbone, et al., “Cannabinoids inhibit gap junctional intercellular communication and activate ERK in a rat liver epithelial cell line,” International Journal of Cancer, vol. 104, no. 1, pp. 12–18, 2003. View at Publisher · View at Google Scholar · View at PubMed
30. D. G. Demuth and A. Molleman, “Cannabinoid signalling,” Life Sciences, vol. 78, no. 6, pp. 549–563, 2006. View at Publisher · View at Google Scholar · View at PubMed
31. Z. Bagi, A. Koller, and G. Kaley, “PPAR$\gamma$ activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles of mice with Type 2 diabetes,” American Journal of Physiology, vol. 286, no. 2, pp. H742–H748, 2004. View at Publisher · View at Google Scholar · View at PubMed
32. D.-H. Cho, Y. J. Choi, S. A. Jo, and I. Jo, “Nitric oxide production and regulation of endothelial nitric-oxide synthase phosphorylation by prolonged treatment with troglitazone: evidence for involvement of peroxisome proliferator-activated receptor (PPAR) $\gamma$-dependent and PPAR$\gamma$-independent signaling pathways,” The Journal of Biological Chemistry, vol. 279, no. 4, pp. 2499–2506, 2004. View at Publisher · View at Google Scholar · View at PubMed
33. H. Y. Ling, S. D. Feng, S. H. Zhou, B. X. Wang, X. Q. Liu, and B. Hu, “Effects of rosiglitazone on aortic function in rats with insulin resistant-hypertension,” Sheng Li Xue Bao, vol. 57, no. 2, pp. 125–131, 2005.
34. J. B. Majithiya, A. N. Paramar, and R. Balaraman, “Pioglitazone, a PPAR$\gamma$ agonist, restores endothelial function in aorta of streptozotocin-induced diabetic rats,” Cardiovascular Research, vol. 66, no. 1, pp. 150–161, 2005. View at Publisher · View at Google Scholar · View at PubMed
35. D. Bishop-Bailey, “Peroxisome proliferator-activated receptors in the cardiovascular system,” British Journal of Pharmacology, vol. 129, no. 5, pp. 823–834, 2000. View at Publisher · View at Google Scholar · View at PubMed
36. W. A. Hsueh and D. Bruemmer, “Peroxisome proliferator-activated receptor $\gamma$: implications for cardiovascular disease,” Hypertension, vol. 43, no. 2, pp. 297–305, 2004. View at Publisher · View at Google Scholar · View at PubMed
37. S. Z. Duan, M. G. Usher, and R. M. Mortensen, “Peroxisome proliferator-activated receptor-$\gamma$-mediated effects in the vasculature,” Circulation Research, vol. 102, no. 3, pp. 283–294, 2008. View at Publisher · View at Google Scholar · View at PubMed
38. N. J. Underdown, C. R. Hiley, and W. R. Ford, “Anandamide reduces infarct size in rat isolated hearts subjected to ischaemia-reperfusion by a novel cannabinoid mechanism,” British Journal of Pharmacology, vol. 146, no. 6, pp. 809–816, 2005. View at Publisher · View at Google Scholar · View at PubMed
39. D. Lamontagne, P. Lépicier, C. Lagneux, and J. F. Bouchard, “The endogenous cardiac cannabinoid system: a new protective mechanism against myocardial ischemia,” Archives des Maladies du Coeur et des Vaisseaux, vol. 99, no. 3, pp. 242–246, 2006.
40. P. Pacher and G. Haskó, “Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning,” British Journal of Pharmacology, vol. 153, no. 2, pp. 252–262, 2008. View at Publisher · View at Google Scholar · View at PubMed
41. S. Bátkai, P. Pacher, D. Osei-Hyiaman, et al., “Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension,” Circulation, vol. 110, no. 14, pp. 1996–2002, 2004. View at Publisher · View at Google Scholar · View at PubMed
42. R. Sarzani, “Endocannabinoids, blood pressure and the human heart,” Journal of Neuroendocrinology, vol. 20, pp. 58–62, 2008. View at Publisher · View at Google Scholar · View at PubMed
43. F. Mach and S. Steffens, “The role of the endocannabinoid system in atherosclerosis,” Journal of Neuroendocrinology, vol. 20, pp. 53–57, 2008. View at Publisher · View at Google Scholar · View at PubMed